CHMS Encourages FDA to Keep Compliance Policy Guide 400.400

3/22/18. The CHMS is encouraging the FDA to keep the Compliance Policy Guide 400.400, entitled “Conditions Under Which Homeopathic Drugs May be Marketed”(CPG 400.400) as it has been, as well as consider homeopathic medicine’s inherently extraordinarily low risk when determining priorities for enforcement of drugs.

Please take the time to submit your constructive comments to the FDA regarding their Draft Guidance on Drug Products Labeled as Homeopathic, issued in December, 2017 by May 21st, 2018.

Leave a Reply